Patents by Inventor John A. Lowe, III

John A. Lowe, III has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Bicyclic inhibitors of histone deacetylase
    Patent number: 10793567
    Abstract: Provided are compounds of the formula and pharmaceutically acceptable salts and composition thereof, which are useful in the treatment of conditions associated with inhibition of HDAC (e.g. HDAC2).
    Type: Grant
    Filed: January 11, 2018
    Date of Patent: October 6, 2020
    Assignee: Rodin Therapeutics, Inc.
    Inventors: Nathan Oliver Fuller, John A. Lowe, III
  • Potassium channel modulators
    Patent number: 10774064
    Abstract: Provided are novel compounds of Formula (I): and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions which can be affected by potassium channel modulation. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with potassium channels.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: September 15, 2020
    Assignee: Cadent Therapeutics, Inc.
    Inventors: Birgitte Langer Eriksen, Magnus Gustafsson, Charlotte Hougaard, Thomas Amos Jacobsen, Martin R. Jefson, Gregg F. Keaney, Jessica Klein, Janus Schreiber Larsen, John A. Lowe, III, John M. McCall, Dorte Strøbæk, Nadia Lybøl von Schoubye
  • HETERO-HALO INHIBITORS OF HISTONE DEACETYLASE
    Publication number: 20200247814
    Abstract: This invention provides compounds that are inhibitors of HDAC2. The compounds (e.g., compounds according to Formula I, II or any of Compounds 100-128 or any of those in Tables 2 or 3) accordingly are useful for treating, alleviating, or preventing a condition in a subject such as a neurological disorder, memory or cognitive function disorder or impairment, extinction learning disorder, fungal disease or infection, inflammatory disease, hematological disease, or neoplastic disease, or for improving memory or treating, alleviating, or preventing memory loss or impairment.
    Type: Application
    Filed: December 26, 2019
    Publication date: August 6, 2020
    Inventors: Martin R. Jefson, John A. Lowe, III, Fabian Dey, Andreas Bergmann, Andreas Schoop, Nathan Oliver Fuller
  • SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF
    Publication number: 20200206189
    Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Application
    Filed: August 9, 2019
    Publication date: July 2, 2020
    Inventors: John A. Lowe, III, M. Amin Khan
  • Bicyclic inhibitors of histone deacetylase
    Patent number: 10696673
    Abstract: Provided herein are compounds and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of conditions associated with inhibition of HDAC (e.g., HDAC2).
    Type: Grant
    Filed: November 12, 2019
    Date of Patent: June 30, 2020
    Assignee: Rodin Therapeutics, Inc.
    Inventors: Nathan Oliver Fuller, John A. Lowe, III
  • BICYCLIC INHIBITORS OF HISTONE DEACETYLASE
    Publication number: 20200148678
    Abstract: Provided herein are compounds and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of conditions associated with inhibition of HDAC (e.g., HDAC2).
    Type: Application
    Filed: November 12, 2019
    Publication date: May 14, 2020
    Inventors: Nathan Oliver Fuller, John A. Lowe, III
  • Prodrugs of Secondary Amine Compounds
    Publication number: 20200087317
    Abstract: The present invention relates to compounds of Formula I:
    Type: Application
    Filed: September 6, 2019
    Publication date: March 19, 2020
    Inventors: Laura Cook Blumberg, John A. Lowe, III, Orn Almarsson, Juan C. Alvarez, Tarek A. Zeidan
  • Bicyclic inhibitors of histone deacetylase
    Patent number: 10519149
    Abstract: Provided herein are compounds and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of conditions associated with inhibition of HDAC (e.g., HDAC2).
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: December 31, 2019
    Assignee: Rodin Therapeutics, Inc.
    Inventors: Nathan Oliver Fuller, John A. Lowe, III
  • BICYCLIC INHIBITORS OF HISTONE DEACETYLASE
    Publication number: 20190337953
    Abstract: Provided herein are compounds and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of conditions associated with inhibition of HDAC (e.g. HDAC2).
    Type: Application
    Filed: January 11, 2018
    Publication date: November 7, 2019
    Inventors: Nathan Oliver Fuller, John A. Lowe, III
  • Spiro-lactam NMDA receptor modulators and uses thereof
    Patent number: 10441572
    Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Grant
    Filed: May 2, 2018
    Date of Patent: October 15, 2019
    Assignee: Aptinyx Inc.
    Inventors: John A. Lowe, III, M. Amin Khan
  • Spiro-lactam NMDA receptor modulators and uses thereof
    Patent number: 10441571
    Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Grant
    Filed: May 2, 2018
    Date of Patent: October 15, 2019
    Assignee: Aptinyx Inc.
    Inventors: John A. Lowe, III, M. Amin Khan
  • Heterobicyclic N-aminophenyl-amides as inhibitors of histone deacetylase
    Patent number: 10421756
    Abstract: This invention provides compounds that are inhibitors of HDAC2. The compounds (e.g., compounds according to Formula (I) or any one of Compounds 100-175) accordingly are useful for treating, alleviating, or preventing a condition in a subject such as a neurological disorder, memory or cognitive function disorder or impairment, extinction learning disorder, fungal disease or infection, inflammatory disease, hematological disease, or neoplastic disease, or for improving memory or treating, alleviating, or preventing memory loss or impairment.
    Type: Grant
    Filed: July 5, 2016
    Date of Patent: September 24, 2019
    Assignee: Rodin Therapeutics, Inc.
    Inventors: Martin R. Jefson, John A. Lowe, III, Fabian Dey, Andreas Bergmann, Andreas Schoop
  • POTASSIUM CHANNEL MODULATORS
    Publication number: 20190218200
    Abstract: Provided are novel compounds of Formula (I): and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions which can be affected by potassium channel modulation. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with potassium channels.
    Type: Application
    Filed: June 2, 2017
    Publication date: July 18, 2019
    Inventors: Birgitte Langer Eriksen, Magnus Gustafsson, Charlotte Hougaard, Thomas Amos Jacobsen, Martin R. Jefson, Gregg F. Keaney, Jessica Klein, Janus Schreiber Larsen, John A. Lowe, III, John M. McCall, Dorte Strøbæk, Nadia Lybøl von Schoubye
  • Spiro-lactam NMDA receptor modulators and uses thereof
    Patent number: 10316041
    Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: June 11, 2019
    Assignee: Aptinyx Inc.
    Inventors: John A. Lowe, III, M. Amin Khan
  • Spiro-lactam NMDA receptor modulators and uses thereof
    Patent number: 10273239
    Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Grant
    Filed: August 2, 2017
    Date of Patent: April 30, 2019
    Assignee: Aptinyx Inc.
    Inventors: John A. Lowe, III, M. Amin Khan
  • Spiro-lactam NMDA receptor modulators and uses thereof
    Patent number: 10253032
    Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Grant
    Filed: July 19, 2017
    Date of Patent: April 9, 2019
    Assignee: Aptinyx Inc.
    Inventors: John A. Lowe, III, M. Amin Khan
  • SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF
    Publication number: 20180250268
    Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Application
    Filed: May 2, 2018
    Publication date: September 6, 2018
    Inventors: John A. Lowe, III, M. Amin Khan
  • SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF
    Publication number: 20180250267
    Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Application
    Filed: May 2, 2018
    Publication date: September 6, 2018
    Inventors: John A. Lowe, III, M. Amin Khan
  • SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF
    Publication number: 20180244680
    Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Application
    Filed: May 2, 2018
    Publication date: August 30, 2018
    Inventors: John A. Lowe, III, M. Amin Khan
  • Spiro-lactam NMDA receptor modulators and uses thereof
    Patent number: 10052308
    Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: August 21, 2018
    Assignee: Aptinyx Inc.
    Inventors: John A. Lowe, III, M. Amin Khan